Murine Monoclonal Antibodies against the Receptor Binding Domain of SARS-CoV-2 Neutralize Authentic Wild-Type SARS-CoV-2 as Well as B.1.1.7 and B.1.351 Viruses and Protect <i>In Vivo</i> in a Mouse Model in a Neutralization-Dependent Manner
Fatima Amanat, Shirin Strohmeier, Wen-Hsin Lee, Sandhya Bangaru, Andrew B. Ward, Lynda Coughlan, Florian Krammer
Abstract
Cross-neutralization of SARS-CoV-2 variants by RBD-targeting antibodies is still not well understood, and very little is known about the potential protective effect of nonneutralizing antibodies in vivo . Using a panel of mouse monoclonal antibodies, we investigate both of these points.
Topics & Concepts
Monoclonal antibodyEpitopeVirologyAntibodyNeutralizationSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)BiologyCoronavirusPhage displayIn vivoEpitope mappingTiterVirusImmunologyCoronavirus disease 2019 (COVID-19)MedicineDiseaseInfectious disease (medical specialty)GeneticsPathologySARS-CoV-2 and COVID-19 ResearchCOVID-19 Clinical Research StudiesAnimal Virus Infections Studies